Mr. Ryoichi Tanaka Joins Telix Japan as Chief Operating Officer

6 August 2021 – Corporate Spotlight | Ryoichi Tanaka joins Telix as COO and Head of Business Development, Telix Pharmaceuticals Japan. 

Telix is delighted to announce that Ryoichi Tanaka has joined the Japan business as Chief Operating Officer and Head of Business Development.

Mr. Tanaka joins from Siemens Healthcare K.K. where most recently he was Head of Medical Policy & Public Affairs. Ryoichi brings with him over 35 years’ experience in radiology and molecular imaging across sales and marketing, business development, and medical policy and government affairs. He currently holds two public positions as Vice Chair of the Committee of Research and Development of JIRA (Japan Medical Imaging and Radiological Systems Industries Association) and Director of Reimbursement of the European Business Council (EBC) in Japan, a position he has held since 2016.

Ryoichi has a Bachelor’s degree in Radiology from Suzuka University of Medical Science, and took a Doctorial course in Nuclear Medicine at Yokohama City University. He obtained his radiological technologist license in 1985 and also has an MBA from Prifysgol Cymru University of Wales in Japan.

On joining Telix, Mr. Tanaka stated, “I am very pleased to join Telix, a global leader and innovator in molecularly targeted radiation (MTR). I look forward to making our MTR products available to Japanese patients and pioneering the Japanese market. Patient access to nuclear medicines in Japan has been limited to date and Telix has an opportunity to change the paradigm. I am proud to be part of that journey.”

Telix Japan President, Dr. Shintaro Nishimura added, “I am delighted to welcome Ryoichi to Telix Japan at this important time in our Company’s evolution. His pedigree in radiology and nuclear medicine, combined with broad experience in business and medical policy, will be instrumental as we prepare for Japanese pivotal studies of our lead investigational imaging products, TLX250-CDx  for renal cancer and Illuccix® for prostate cancer.” 

To view the full media release please click here

To return to our home page please click here.